Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme gets cold tissue welding technology:

This article was originally published in Clinica

Executive Summary

Genzyme Tissue Repair will get exclusive rights for the development and commercialisation of PhotoBioMed's photoactive tissue welding technology for all orthopaedic purposes. Genzyme will make an initial payment to the Dallas-based company and subsequent milestone and royalty payments. PhotoBioMed's technology uses a photochemical compound which, when light activated, interacts with collagen fibres in the tissue, cross-linking the proteins and welding torn tissue without heat. Genzyme, of Cambridge, Massachusetts, will first develop applications for meniscal repair.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT082063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel